IONSHealthcare · BiotechnologyThe 24 Wall Street analysts covering Ionis Pharmaceuticals, Inc. hold a median 12-month price target of $85 — +92.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 14 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Ionis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (90): The share price has been relatively steady.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IONS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +92.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 22 Sept 2026 | JP Morgan | Maintains | Overweight | $76 → $70 |
| 15 Sept 2026 | Guggenheim | Maintains | Buy | $89 → $80 |
| 15 Sept 2026 | Guggenheim | Maintains | Buy | — |
| 9 Sept 2026 | Barclays | Maintains | Overweight | $90 → $85 |
| 9 Sept 2026 | Barclays | Maintains | Overweight | — |
| 8 Sept 2026 | BMO Capital | Maintains | Market Perform | — |
| 8 Sept 2026 | BMO Capital | Maintains | Market Perform | $61 → $54 |
| 8 Sept 2026 | Canaccord Genuity | Maintains | Buy | $95 → $85 |
| 8 Sept 2026 | Canaccord Genuity | Maintains | Buy | — |
| 8 Sept 2026 | Goldman Sachs | Maintains | Neutral | $69 → $56 |
| 8 Sept 2026 | Goldman Sachs | Maintains | Neutral | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $115 → $100 |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2026 | Morgan Stanley | Maintains | Overweight | — |
| 8 Sept 2026 | Morgan Stanley | Maintains | Overweight | $110 → $104 |
| 4 Sept 2026 | BMO Capital | Maintains | Market Perform | $60 → $61 |
| 4 Sept 2026 | BMO Capital | Maintains | Market Perform | — |
| 4 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $115 |
| 4 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IONS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Ionis Pharmaceuticals, Inc. returned −39.1% against +16.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 16% of US stocks
Cheaper than 6% of US stocks
Cheaper than 87% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 18% of US stocks
Higher than 8% of US stocks
Higher than 13% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ionis Pharmaceuticals, Inc. has a market value of $7.0B and an enterprise value of $7.3B.
Revenue in the twelve months to 30 June 2026: $874.1M. The latest quarter shrank 40.7% year on year.
Net income over the same four quarters: −$565.2M, a −64.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.46.
Free cash flow in the twelve months to 30 June 2026: −$567.5M.
Trailing P/E: −17.8×; forward P/E: −38.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ionis Pharmaceuticals, Inc. employs 1,480 people — $591K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ionis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alnylam lowered its full-year revenue guidance, citing slower-than-expected Amvuttra sales. Ionis experienced two pipeline setbacks on the same day in July.
Why it matters — Ionis watchers may note the reported setbacks as context when comparing the companies’ recent challenges.
Novartis received FDA approval to expand Rhapsido’s label to include symptomatic dermographism, broadening its chronic hives opportunity. The excerpt notes the expansion comes as pipeline setbacks raise pressure for growth.
Why it matters — The item concerns a competitor’s immunology drug and provides industry context for IONS watchers, but the excerpt gives no direct Ionis-specific development.
Zacks Investment Research highlighted Ionis Pharmaceuticals among four RNA therapeutics stocks—alongside Alnylam, Wave Life Sciences, and Arcturus—that are advancing innovative treatments targeting a range of diseases as the field gains momentum.
Why it matters — The piece positions Ionis as a leading innovator within a growing and increasingly competitive RNA therapeutics space, reinforcing its relevance to investors tracking the sector.
Ionis Pharmaceuticals reported positive late-stage results for two partnered drugs: ulefnersen met its endpoint in an ALS trial, and sefaxersen reduced proteinuria in a phase III study.
Why it matters — Positive phase III outcomes for these partnered programs could support the progress and value of Ionis' pipeline and collaborations.
Ionis and its licensing partner Roche shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of sefaxersen, an investigational RNA-targeted therapy for adults with primary IgA nephropathy. The results relate to the first RNA-targeted therapy for this autoimmune kidney disease.
Why it matters — The interim Phase 3 data for sefaxersen is a key development milestone for Ionis' investigational kidney disease program and its partnership with Roche.
The 24 Wall Street analysts covering Ionis Pharmaceuticals, Inc. have a median 12-month price target of $85, with estimates ranging from $54 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Ionis Pharmaceuticals, Inc., 19 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ionis Pharmaceuticals, Inc. 43 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Ionis Pharmaceuticals, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (90 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +92.7% from the last close, and Ticker Nerd's factor model ranks Ionis Pharmaceuticals, Inc. 43 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ionis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IONS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $54 to $105 over the next 12 months.
Ionis Pharmaceuticals, Inc. returned -39.1% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines.
The most recent item we track (The Motley Fool, 10 Oct 2026): "Alnylam vs. Ionis: Here's the Better Bad-News Buy". Alnylam lowered its full-year revenue guidance, citing slower-than-expected Amvuttra sales. Ionis experienced two pipeline setbacks on the same day in July.
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and cardiometabolic care, as well as other high-need therapeutic areas. The company currently markets several medicines for conditions such as spinal muscular atrophy, hereditary amyloidosis, amyotrophic lateral sclerosis, and certain rare cardiovascular and metabolic disorders. Ionis also maintains an active pipeline of investigational programs and collaborates with pharmaceutical partners to expand the reach of its platform. Headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a significant role in the biotechnology market as a leading developer of RNA-based therapeutics.
CEO Dr. Brett P. Monia Ph.D. · 1,480 employees · United States · https://www.ionis.com
